COX-2 Advisory Committee May Decide Fate of Pfizer’s Bextra
The commercial future of Pfizer's Bextra may be at stake during FDA's early 2005 advisory committee discussion of the COX-2 inhibitor class
The commercial future of Pfizer's Bextra may be at stake during FDA's early 2005 advisory committee discussion of the COX-2 inhibitor class